Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.

Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME, Lange JM; ATHENA Study Group.

Ther Drug Monit. 2003 Feb;25(1):73-80.

PMID:
12548148
2.

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance.

Hugen PW, Burger DM, Aarnoutse RE, Baede PA, Nieuwkerk PT, Koopmans PP, Hekster YA.

Ther Drug Monit. 2002 Oct;24(5):579-87.

PMID:
12352928
3.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
4.

Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast.

Hugen PW, Burger DM, Koopmans PP, Stuart JW, Kroon FP, van Leusen R, Hekster YA.

Pharm World Sci. 2002 Jun;24(3):83-6.

PMID:
12136744
5.

Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring.

Hugen PW, Langebeek N, Burger DM, Zomer B, van Leusen R, Schuurman R, Koopmans PP, Hekster YA.

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):324-34.

PMID:
12131570
6.

Pros and cons of therapeutic drug monitoring of antiretroviral agents.

Burger DM, Aarnoutse RE, Hugen PW.

Curr Opin Infect Dis. 2002 Feb;15(1):17-22.

PMID:
11964901
7.

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM.

Clin Pharmacol Ther. 2002 Jan;71(1):57-67.

PMID:
11823758
8.

Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?

Burger DM, Siebers MC, Hugen PW, Aarnoutse RE, Hekster YA, Koopmans PP.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):101-2. No abstract available.

PMID:
11782597
9.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project.

Arch Intern Med. 2001 Sep 10;161(16):1962-8.

PMID:
11525698
10.

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA.

AIDS. 2001 May 25;15(8):991-8.

PMID:
11399981
11.

A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.

Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP, Prins JM, van der Poll T, ten Veen JH, Mulder JW, Meenhorst PL, Blok WL, van der Meer JT, Reiss P, Lange JM.

J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):218-24.

PMID:
11242194
12.

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, Scherpbier HJ, Hoetelmans RM, Vulto AG, de Groot R; Dutch Study Group for Children with HIV-1 Infection.

Antimicrob Agents Chemother. 2001 Mar;45(3):701-5.

13.

No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.

Schippers EF, Hugen PW, den Hartigh J, Burger DM, Hoetelmans RM, Visser LG, Kroon FP.

AIDS. 2000 Dec 1;14(17):2794-5. No abstract available.

PMID:
11125902
14.

Dose-finding study of a once-daily indinavir/ritonavir regimen.

Hugen PW, Burger DM, ter Hofstede HJ, Koopmans PP, Stek M, Hekster YA, Reiss P, Lange JM.

J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):236-45.

PMID:
11115954
15.

Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir.

Hugen PW, Burger DM, de Graaff M, ter Hofstede HJ, Hoetelmans RM, Brinkman K, Meenhorst PL, Mulder JW, Koopmans PP, Hekster YA.

Ther Drug Monit. 2000 Aug;22(4):437-45.

PMID:
10942185
16.

Development of an indinavir oral liquid for children.

Hugen PW, Burger DM, ter Hofstede HJ, Koopmans PP, Hekster YA.

Am J Health Syst Pharm. 2000 Jul 15;57(14):1332-9.

PMID:
10918923
17.

Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

Hugen PW, Burger DM, Brinkman K, ter Hofstede HJ, Schuurman R, Koopmans PP, Hekster YA.

Ann Pharmacother. 2000 Apr;34(4):465-70.

PMID:
10772431
18.

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.

Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA.

Antivir Ther. 1998;3(4):215-20.

PMID:
10682141
19.

Once-daily indinavir plus ritonavir: preliminary results of the PIPO study.

Burger DM, Hugen PW, van der Ende ME, van Wijngaarden P, Aarnoutse RE, Reiss P, Lange JM.

AIDS. 2000 Nov 10;14(16):2621-3. No abstract available.

PMID:
11101081
20.

Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.

Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA.

J Chromatogr B Biomed Sci Appl. 1999 Apr 30;727(1-2):139-49.

PMID:
10360433
21.

Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir.

Burger DM, Hugen PW, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA.

AIDS. 1998 Oct 22;12(15):2080-2. No abstract available.

PMID:
9814882
22.

Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients.

Brinkman K, Kroon F, Hugen PW, Burger DM.

AIDS. 1998 Mar 26;12(5):537. No abstract available.

PMID:
9543457

Supplemental Content

Loading ...
Support Center